Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent.~* Man or woman between 18 and 70 years of age.~* Ileal Pouch-Anal Anastomosis (IPAA) after colectomy for ulcerative colitis~* Active pouchitis, defined as a modified pouch disease activity index (mPDAI) ≥ 5 and a history of ≥ 4 antibiotic therapies for pouchitis in the last 12 months~or~- Need for ongoing antibiotic therapy (\> 4 weeks) to maintain clinical remission and a history of at least 2 attempts in the last 24 months to stop antibiotic therapy resulting in pouchitis episodes.~Exclusion Criteria:~* Treatment with biologics (e.g. infliximab, adalimumab, golimumab, vedolizumab)~* Treatment with immunomodulators (azathioprine, 6-mercaptopurine (6-MP), methotrexate), steroids or any investigational drugs~* Use of cholestyramine~* Crohn's disease of the pouch~* Known cytomegalovirus infection of the pouch~* Clostridium difficile infection~* Isolated cuffitis~* Clinical significant strictures of the pouch inlet or outlet~* Concurrent intestinal obstruction~* History of familial adenomatous polyposis~* History of uncontrolled lactose intolerance~* History of confirmed (serological test and/or histology) celiac disease~* Pregnancy, breast feeding, or planning to become pregnant during the trial~* Non - steroidal inflammatory medications (NSAIDs) as long-term treatment, defined as use for at least 4 days a week each month~* Dysphagia (oropharyngeal, esophageal, functional, neuromuscular)~* History of recurrent aspiration episodes~* Proven Gastroparesis~* Allergy to the following generally regarded as safe ingredients (GRAS): glycerol, acid resistant hypromellose (HPMC), gellan gum, cocoa butter, titanium dioxide~* Adverse event attributable to previous FMT~* Allergy/intolerance to pump inhibitor therapy~* Any condition for which the investigator thinks the FMT treatment may pose a health risk (e.g. severely immunocompromised)~* Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial~* During the trial period until one week after the trial end: Non-use of appropriate contraceptives in females of childbearing potential (e.g. condoms, intrauterine device (IUD), hormonal contraception, or other means considered adequate by the responsible investigator) or in males with a child-fathering potential (condoms, or other means considered adequate by the responsible investigator during treatment - Well-founded doubt about the patient's cooperation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Active FMT, then open label FMT (Type: ACTIVE_COMPARATOR): Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
- Placebo FMT, then open label FMT (Type: PLACEBO_COMPARATOR): Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.

Based on this trial design, predict the completion outcome and termination type (if applicable).